Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories has been named as a defendant in multiple lawsuits related to the Revlimid antitrust action in the United States. The company, along with other defendants, has filed motions to dismiss these lawsuits and plans to vigorously defend its position. The outcome of these legal challenges could impact Dr. Reddy’s stock performance and market perception.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
